Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem®) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study.

Yehenew A Ebstie,Sultan Suleman,Zelalem Desalegn,Tefera Belachew,Ahmed Zeynudin

doi:10.1186/s12936-015-0744-x

Yehenew A Ebstie, Sultan Suleman + Show 3 more

Open Access

https://doi.org/10.1186/s12936-015-0744-x

Copy DOI

Journal: Malaria journal	Publication Date: Jun 5, 2015
Citations: 23	License type: CC BY 4.0

Affiliation: Addis Ababa University, Jimma University

Abstract

BackgroundMalaria is a complex disease, which varies in its epidemiology and clinical manifestation. Although artemether-lumefantrine has been used as first-line drug for uncomplicated Plasmodium falciparum malaria in Bahir Dar district since 2004, its efficacy has not yet been assessed. The main objective of this study was to quantify the proportion of patients with uncomplicated falciparum malaria who were prescribed artemether-lumefantrine and who failed treatment after a 28-day follow-up.MethodsThe research team attempted to conduct an observational cohort study on the assessment of therapeutic efficacy and safety of artemether-lumefantrine in falciparum malaria patients aged over five years in Bahir Dar district from March to July 2012.ResultsAmong 130 participants in the study, 60 % were males with 1:5 male to female ratio. The mean of asexual parasitaemia load was 8675 parasites/μL and 96.1 % participants were free from parasitaemia at day 3. At the end of the study, 98.5 % of participants showed adequate clinical and parasitological response of the drug. In the study, only 1.5 % of participants were shown late parasitological failure between seventh and 14th day follow-up and 1.3 % of participants were free from anaemia at the end of follow-up.ConclusionAccording to the research findings, artemether-lumefantrine fulfilled the inclusion criteria of WHO as first-line drug and continues to be the drug of choice for the treatment of uncomplicated falciparum malaria. Outputs from this study should be supported through advanced molecular techniques and blood concentration and pharmaco-vigilance of the drug.

Highlights

Malaria is a complex disease, which varies in its epidemiology and clinical manifestation
According to a World Health Organization (WHO) report, the global incidence of the disease was 402 million in 107 malaria-endemic countries, and among those, 57 % of cases occurred in sub-Saharan Africa [1, 2] and 72 % of African cases were due to Plasmodium
Many studies have indicated that AL is a drug which fulfills WHO requirements of a drug of choice for the treatment of uncomplicated malaria [14, 15]

Summary

Introduction

Malaria is a complex disease, which varies in its epidemiology and clinical manifestation. Artemether-lumefantrine has been used as first-line drug for uncomplicated Plasmodium falciparum malaria in Bahir Dar district since 2004, its efficacy has not yet been assessed. The main objective of this study was to quantify the proportion of patients with uncomplicated falciparum malaria who were prescribed artemether-lumefantrine and who failed treatment after a 28-day follow-up. According to a World Health Organization (WHO) report, the global incidence of the disease was 402 million in 107 malaria-endemic countries, and among those, 57 % of cases occurred in sub-Saharan Africa [1, 2] and 72 % of African cases were due to Plasmodium. Many studies have indicated that AL is a drug which fulfills WHO requirements of a drug of choice for the treatment of uncomplicated malaria [14, 15]. The purpose of this study was to determine the degree to which episodes of uncomplicated falciparum malaria, in patients age five years and above, had been treated with a recommended anti-malarial regimen in the area

Objectives

Methods

Results

Conclusion